Related by context. All words. (Click for frequent words.) 87 Psoriasis Area 72 Crohn Disease Activity 71 Index CDAI 71 CDAI 69 nasal symptom 69 baseline PASI 68 Rating Scale MADRS 68 Visual Analogue Scale VAS 68 Severity Index 68 Montgomery Asberg Depression 68 achieved PASI 68 DAS# CRP 67 DLQI 67 NIH CPSI 67 DAS# [002] 67 Scale EDSS 67 Montgomery Åsberg Depression 67 PASI 67 PANSS total 67 Brief Psychiatric 67 Global Impression CGI 67 PASI scores 66 UPDRS motor 66 HDRS 66 Score DAS 65 UPDRS 65 Expanded Disability Status 65 demonstrated clinically meaningful 65 8mg/kg 65 Fibromyalgia Impact Questionnaire 65 Ejection Fraction 65 Unified Parkinson Disease 65 plus methotrexate 65 Negative Syndrome 65 RECIST Response Evaluation Criteria 65 CCyR 64 Disease Activity 64 achieved ACR# 64 certolizumab 64 CNS LS 64 IBDQ 64 CDAI score 64 mg TID 64 ACR# response 64 Respiratory Symptoms 64 ADCS CGIC 64 4mg/kg 63 Visual Analog Scale 63 ACTEMRA TM 63 clinically meaningful improvement 63 Rating Scale UPDRS 63 NIHSS 63 oxycodone CR 63 YMRS 63 Index CDAI score 63 Scale EDSS score 63 PANSS 63 tipranavir r 63 bortezomib refractory 63 Score IPSS 63 DAS# scores 63 BILAG 63 lopinavir r arm 63 bronchial hyperresponsiveness 63 Health Assessment Questionnaire 63 BMI z 63 SELENA SLEDAI 63 IRLS 63 FOLPI 63 relapsed MM 63 hematologic parameters 63 tolterodine ER 63 PASI score 63 MADRS score 63 ADAS cog 63 WOMAC pain 63 International Prostate Symptom 62 Primary endpoints 62 DAS# remission 62 sUA 62 GERD symptom 62 NYHA functional class 62 fasting plasma glucose FPG 62 mg QD 62 Follicular Lymphoma 62 receiving golimumab 62 Skin sterol 62 estimated glomerular filtration 62 SGRQ 62 Alzheimer Disease Assessment 62 Response Evaluation Criteria 62 â ‰ ¥ 62 NIS LL 62 elevated ALT 62 aspartate aminotransferase AST 62 Solid Tumors criteria 62 MCyR 62 non menstrual pelvic 62 Thrombolysis 62 ADAS Cog 62 mucosal healing 62 hip BMD 62 MoxDuo TM IR 62 ACR Pedi 62 Neuropsychiatric Inventory 62 alanine aminotransferase ALT 62 FluCAM arm 62 Demonstrate Significant 62 glycosylated hemoglobin HbA1c 62 HAQ DI 62 IRLS score 62 x ULN 62 Retreatment 61 haematologic 61 posttreatment 61 serum phosphate 61 postintervention 61 achieving PASI 61 mcg QD 61 Secondary endpoints included 61 Inventory BPI 61 Secondary efficacy endpoints 61 specific antigen PSA 61 Functional Assessment 61 retinal thickness 61 cEVR 61 Pharmacokinetic parameters 61 achieved CCyR 61 Main Outcome Measures 61 REYATAZ r arm 61 EDSS score 61 confirmed CCyR 61 Score DAS# 61 epoetin alpha 61 CIMZIA TM 61 serologically active patients 61 moderate renal impairment 61 BPH symptom 61 Y BOCS 61 HBeAg seroconversion 61 pain subscale 61 desvenlafaxine succinate 61 undetectable HBV DNA 61 Symptom severity 61 lumbar spine BMD 61 Scale PANSS 61 HER2 expression 61 Rate ORR 61 APACHE II 61 unresectable HCC 61 morphometric vertebral fractures 60 WOMAC 60 tapentadol ER 60 leucopenia 60 mg BID 60 mL/min/#.# m 2 60 timepoints 60 TNSS 60 IPSS 60 liver histology 60 serum aminotransferase levels 60 Negative Symptoms 60 Severity MSCS score 60 secondary efficacy endpoint 60 Secondary endpoints include 60 elevated transaminases 60 carotid artery intima media 60 somatostatin analog 60 Endothelial function 60 Hamilton Anxiety Scale 60 microbiological eradication 60 Status Scale EDSS 60 Histologic 60 Outcome Measures 60 serum urate 60 Prolongs Survival 60 WOMAC scores 60 calculated creatinine clearance 60 induration 60 urine albumin 60 PSA nadir 60 #mg/day [001] 60 hemoglobin A1c HbA1c 60 Ishak fibrosis score 60 ACR# ACR# 60 NWEA MAP 60 PCWP 60 biopsy Gleason 60 Autologous Stem Cell Transplantation 60 Engerix B 60 serum cortisol 60 evaluable subjects 60 salmeterol fluticasone propionate 60 Non Responders 60 QIDS SR 60 iPTH 60 Infusion Reactions Severe 60 aminotransferases 60 HbA 1c 60 OSDI 60 CIMZIA TM certolizumab pegol 60 Secondary endpoints 60 EDSS scores 60 PsA 60 mg BID dose 60 Postoperatively 60 PREZISTA r arm 60 briakinumab 60 lactate dehydrogenase LDH 60 postdose 59 mcg BID 59 mcg Albuferon 59 HAM D 59 serum IGF 59 serum phosphorous 59 Brief Pain 59 HRQoL 59 FFNS 59 Ocular Surface Disease 59 CFQ R 59 postprocedure 59 mineral density BMD 59 corticosteroid dose 59 Solid Tumors 59 cough dyspnea 59 Platinol ® 59 QTcF 59 HBeAg negative patients 59 -#.# log# 59 SGOT 59 neutropaenia 59 MADRS 59 alteplase 59 GAMMAGARD 59 fluticasone salmeterol 59 Seattle Angina Questionnaire 59 ug kg 59 mcg albinterferon alfa 2b 59 erythrocyte sedimentation rate 59 aspartate aminotransferase 59 Timed Walk 59 aminotransferase ALT 59 6MWD 59 transaminases 59 symptom severity 59 Symptom Checklist 59 CIMZIA ™ 59 AVODART 59 IELT 59 Flu Cy 59 oral antidiabetic medication 59 antibody titer 59 abdominal pain abdominal discomfort 59 Improves Outcomes 59 mg/m2 dose 59 intraobserver 59 eNO 59 scores TNSS 59 HCV RESPOND 2 59 Cystic Fibrosis Questionnaire Revised 59 timepoint 59 Castration Resistant Prostate Cancer 59 PSADT 59 INCB# [003] 59 intravascular hemolysis 59 HbA 1c levels 59 preoperatively 59 Patients Receiving 59 Scale Cognitive Subscale 59 RAPAFLO R 59 glomerular filtration 59 NMIBC 59 systemic corticosteroid 59 erection hardness 59 Scale cognitive subscale 59 EUFLEXXA R 59 Naive Patients 59 Metastatic Prostate Cancer 59 urinary albumin 59 ADHD RS 59 daunorubicin 59 hemoglobin A1c levels 59 OPT CHF 59 IU ml 59 ara C 59 intact parathyroid hormone 59 severe exacerbations 59 State Examination MMSE 59 doxorubicin cyclophosphamide 59 UPDRS Part III 59 Folfox 59 CP CPPS 59 urinary N telopeptide 58 lumbar spine bone 58 μg dose 58 prospectively stratified 58 Tumor Response 58 BEXXAR Therapeutic Regimen 58 ARB telmisartan 58 solifenacin 58 seroprotection 58 budesonide pMDI 58 ALT elevations 58 inflammatory lesions 58 Platelet counts 58 trough FEV1 58 subscore 58 biochemical relapse 58 dyspnoea 58 deep venous thromboses 58 CRp 58 plasma HCV RNA 58 ALS Functional 58 cytogenetic response 58 FOLFOX6 58 #mg BID [001] 58 Mean Symptom Complex 58 HSCT 58 Symptom Score 58 clinically meaningful improvements 58 CR CRu 58 dapagliflozin plus 58 spirometric 58 gastroduodenal 58 #.#ng/ml 58 adjunctive placebo 58 exploratory endpoints 58 HAMD 58 #mg QD [002] 58 Hypertrophy 58 serum testosterone 58 hepatitis C genotype 58 ecchymosis 58 quantitative coronary angiography 58 FluCAM 58 ertapenem 58 Pharmacodynamic 58 etanercept 58 clinically evaluable patients 58 alanine transaminase ALT 58 SGPT 58 HOMA IR 58 dactylitis 58 preintervention 58 Ashworth Scale 58 lymphopenia 58 hypophosphatemia 58 SUVmax 58 Lower Limb 58 Hb A1C 58 ACR# responses 58 achieved statistical significance 58 HAM D# 58 hepatic enzyme 58 Partial Response 58 Natalizumab 58 permanently discontinue Vectibix 58 rotigotine 58 nausea somnolence 58 erosive gastritis 58 baseline FEV 58 exhaled NO 58 CHOP chemotherapy 58 intradermal injections 58 salmeterol fluticasone 58 symptomatic VTE 58 PANSS Positive 58 % Confidence Interval 58 mg RDEA# 58 rosuvastatin #mg 58 FDG PET imaging 58 endoscopic remission 58 spontaneous bowel movements 58 Adjuvant Treatment 58 Score TOS 58 posttest 58 tumor progression TTP 58 Angiographic 58 ALT AST 58 Pegasys ® 58 Pain Intensity 58 partial remissions 58 glycosylated hemoglobin levels 58 receiving XGEVA 58 prednisone prednisolone plus 58 Solid Tumors RECIST 58 histologic subtype 58 Oral Fingolimod 58 progression TTP 58 maximal treadmill 58 histologically proven 58 CPAP adherence 58 EBMT criteria 58 FDG-PET/CT 58 STRIDE PD 58 ARCOXIA 58 ng dl 58 pT3 58 ‰ ¥ 58 CIN3 58 fasting insulin 58 NNT = 58 hepatic lesions 58 mg ustekinumab 58 reduce serum phosphate 58 receiving PEGINTRON 58 Atopic Dermatitis 58 BARACLUDE ® 57 ETDRS 57 Rating Scale 57 CR nPR 57 glycated hemoglobin HbA1c 57 Rheumatoid Arthritis Patients 57 INVEGA ® 57 ACR# [002] 57 ALA PDT 57 pmol L 57 amoxicillin clavulanate 57 Stroke Scale NIHSS 57 5 Fluorouracil 57 complete cytogenetic 57 SF #v# 57 #μg [001] 57 ug dose 57 μg doses 57 Cardiorespiratory fitness 57 Persistent Sleep 57 rhinoconjunctivitis 57 Demonstrated Significant 57 Pain Rating Scale 57 Breslow thickness 57 left ventricular diastolic 57 PEG IFN 57 complete cytogenetic response 57 neutropenia thrombocytopenia 57 vitreous haze 57 tissue oxygenation 57 Hormone Refractory Prostate Cancer 57 μg kg 57 Soft Tissue Sarcoma 57 #.#mg/dL 57 Metastatic Renal Cell Carcinoma 57 receiving highly emetogenic 57 CLL SLL 57 azilsartan medoxomil 57 TLUS 57 KRAS mutations occur 57 headache abdominal pain 57 PSQI 57 F FDG PET 57 hours postdose 57 cTnT levels 57 erythema redness 57 mTSS 57 comparator arm 57 nondiabetic patients 57 System IPSS 57 Histological 57 3mg/kg 57 treatment naïve genotype 57 infliximab monotherapy 57 baseline LDH 57 nonmetastatic 57 HADS 57 LV ejection fraction 57 peginterferon alfa 2a 57 oral allopurinol 57 Subgroup analysis 57 salivary cortisol 57 QD dosing 57 Hematologic 57 creatinine clearance 57 methotrexate monotherapy 57 serum lipid levels 57 pulmonary metastases 57 CSBMs 57 Visual Analog 57 Beck Anxiety Inventory 57 ribavirin RBV 57 statin monotherapy 57 Doxil ® 57 Cystatin C 57 fasting plasma glucose 57 Distress Scale 57 Common Toxicity Criteria 57 transaminase elevations 57 Fracture Risk 57 gastrointestinal perforation 57 glycated hemoglobin 57 Malignant Glioma 57 severe NCI CTC 57 nasal aerosol 57 Cholinesterase Inhibitors 57 adalimumab 57 Assessment Scale 57 mg kg dose 57 NATRECOR R 57 See WARNINGS 57 Shows Statistically Significant 57 ARIXTRA 57 hepatic enzymes 57 LEXIVA r 57 icatibant 57 stage IIIb IV 57 ritonavir boosted 57 arterial oxygen saturation 57 macroalbuminuria 57 histologically confirmed 57 AST ALT 57 placebo dexamethasone 57 analgesic efficacy 57 vincristine doxorubicin 57 mitoxantrone plus 57 ALT normalization 57 fasting plasma 57 DOXIL 57 mild renal insufficiency 57 FOLFIRI alone 57 Solid Tumours 57 serum prostate 57 EMBLEM TM 57 #mg/day [002] 57 Treated Patients 57 headache nasopharyngitis 57 Pemetrexed 57 Median survival 57 Viral load 57 % CI #.#-#.# [007] 57 PANSS scores 57 serum urate levels 57 galiximab 57 Chemotherapy Improves 57 CI -#.# 57 hematological parameters 57 HRQL 57 TNF Tumor Necrosis Factor 57 death reinfarction 57 concomitant medications 57 SBM frequency 57 N telopeptide 57 mRS 57 paresthesias 57 GH deficiency 57 bioavailable testosterone 57 periprocedural 57 APTIVUS r 57 weekly CSBMs 56 RECIST criteria 56 mineral density 56 albumin excretion rate 56 serum ferritin 56 pharmacodynamic PD 56 receiving VICTRELIS 56 Juvenile Idiopathic Arthritis 56 heFH 56 Advanced Renal Cell 56 tolvaptan 56 underwent surgical resection 56 HIV HCV coinfected 56 diabetes mellitus DM 56 International Prognostic Scoring 56 ADHD Rating Scale 56 Lymphocytic 56 venous stasis ulcers 56 Dyspnea 56 QVAR ® 56 recurrent glioblastoma multiforme 56 binary restenosis 56 Acute Physiology 56 definite stent thrombosis 56 overt nephropathy 56 ejection fractions 56 transaminase levels 56 Prospective Randomized 56 HUMIRA achieved PASI 56 HBV DNA levels 56 clinically meaningful reductions 56 antiretroviral naïve 56 rapid virologic response 56 Coronary artery calcium 56 NHANES III 56 fatigue asthenia 56 Physical Function 56 MYCAMINE 56 juvenile idiopathic arthritis 56 dosed intravenously 56 CANCIDAS 56 lymphocytosis 56 Fasting blood glucose 56 TURBT 56 Virologic 56 P = .# 56 Free Survival PFS 56 complete Early Virological 56 response CCyR 56 Tiotropium 56 alfa 2a 56 alanine aminotransferase 56 ng dL 56 sweat chloride 56 Severe Asthma 56 VELCADE melphalan 56 adenotonsillectomy 56 Glasgow Coma Scale 56 depressive symptom 56 enthesitis 56 Operative mortality 56 XIENCE V PROMUS Stent 56 HCV Genotype 56 submaximal 56 diarrhea nausea fatigue 56 HPA axis suppression 56 Peginterferon Alfa 2a 56 subscores 56 hypomagnesemia 56 Rating Scale BPRS 56 BENICAR 56 underwent resection 56 Median PFS 56 BENICAR HCT 56 Main Outcome Measure 56 Kaplan Meier estimates 56 asthma rhinitis 56 glycated hemoglobin levels 56 Myocardial Infarction TIMI 56 Hypomagnesemia occurred 56 proctitis 56 TMC# r 56 ALT elevation 56 hepatic cirrhosis 56 virologic responses 56 ADCS ADL 56 IIEF 56 chemoradiation therapy 56 dosing cohort 56 mcg kg 56 neurologic progression 56 colesevelam HCl 56 CYT# QbG# 56 Cardiac Resynchronization 56 phosphorylated tau 56 Functional Outcomes 56 Decitabine 56 sustained virologic response 56 UPDRS scores 56 EQ 5D 56 Capacity FVC 56 laboratory abnormalities 56 GSK# [001] 56 FDG PET scans 56 AGILECT R 56 asthenia fatigue 56 incidence ≥ 56 bone marrow reticulin deposition 56 hepatorenal syndrome 56 biochemical recurrence 56 bronchoalveolar lavage 56 isoprostane 56 Etanercept 56 Systemic Sclerosis 56 triamcinolone 56 conjunctival hyperemia 56 dose escalation phase 56 neutropenia febrile neutropenia 56 patients evaluable 56 linaclotide treated 56 subscale scores 56 Ischaemic 56 NSABP B 56 vitreous floaters 56 HBeAg positive patients 56 Erectile Function IIEF 56 Claudication 56 peak VO2 56 detectable HCV RNA 56 receiving APTIVUS r 56 chills fever headache 56 pCR 56 Non inferiority 56 Primary Endpoint 56 CSBM 56 μg L 56 pruritis 56 methacholine challenge 56 FDG uptake 56 UACR 56 Secondary Hyperparathyroidism 56 FACIT Fatigue 56 -#.# ± [002] 56 Kidney Disease Outcomes 56 DLTs 56 ECOG PS 56 hyperphenylalaninemia HPA due 56 metastatic CRC 56 piperacillin tazobactam 56 cervical intraepithelial neoplasia 56 remission CR 56 ropivacaine 56 Septic Shock 56 paraprotein 56 HbA1C levels 56 neutrophil counts 56 leukocyte counts 56 nmol l 56 IFN α 56 postop 56 pharmacokinetic PK profile 56 serum HBV DNA 56 prospectively defined 56 QRS duration 56 preoperative PSA 56 Hepatitis C Genotype 56 interrater reliability 56 STELARA 56 OAB symptoms 56 highest tertile 56 Depressive Symptoms 56 CIN2 + 56 alicaforsen enema 56 Hamilton Rating Scale 56 undetectable HCV RNA 56 certolizumab pegol 56 graft occlusion 56 LVEF 56 serum phosphate levels 56 Visual Analogue Scale 56 -5 -6 56 Zyclara 56 Hematocrit 56 #mg/m# [001] 56 oral levofloxacin 56 mucosal inflammation 56 daily subcutaneous injections 56 microgram kg 56 urodynamic parameters 56 -#.# log# copies mL 56 Hyperlipidemia 56 sustained virological response 56 mg qd 56 colorectal adenoma 56 μmol L 56 methacholine 56 IBS C 56 TYGACIL 56 CLINICAL PHARMACOLOGY 56 mCi kg 56 Postoperative 56 p = NS 56 fludarabine cyclophosphamide 56 pegylated interferon alfa 56 receiving prophylactic anticoagulation 56 resected pancreatic cancer 56 cytogenetic responses 56 Renal Function 56 point Likert scale 56 minimally symptomatic 56 -#.# mg dL [001] 56 Tumor shrinkage 56 clinicopathological 56 Single Dose 56 Kellgren Lawrence 56 Traficet EN 56 #mg/m# [002] 56 plasma leptin 56 Adalimumab 56 adalimumab Humira 56 stage IIIB 56 weekly intravenous infusions 56 carotid intima media 56 virologic response 55 echocardiographic parameters 55 Events MACE 55 Bone Mineral Density 55 gadolinium enhancing lesions 55 microalbumin 55 SELENA SLEDAI score 55 pain palliation 55 Placebo Controlled Trial 55 cinacalcet 55 RENAL 55 coinfected patients 55 hydroxyvitamin D levels 55 mean ± SEM 55 rt PA 55 Relapsing Multiple Sclerosis 55 Endocrine Therapy 55 titration phase 55 Negative Symptom Scale 55 graft dysfunction 55 serum clusterin levels 55 C Reactive Protein 55 airway hydration 55 RECIST 55 Perforomist Inhalation Solution 55 See CLINICAL PHARMACOLOGY 55 anemia hemoglobin 55 NYHA 55 R# #mg BID 55 Pediatric Patients 55 dizziness nausea diarrhea 55 #mg BID [003] 55 RAPTIVA 55 Diabetic Neuropathy 55 Baseline characteristics 55 Known hypersensitivity 55 Cognitive Function 55 erythema 55 abnormal cytology 55 #q# deletion syndrome 55 Showed Significant 55 Relapsing Remitting Multiple Sclerosis 55 gadolinium enhancing 55 Sustained Efficacy 55 metastatic malignant 55 knee osteoarthritis OA 55 titrated glipizide 55 Renal Insufficiency 55 artery stenosis 55 #.#/#.# mmHg [001] 55 Hb A1c 55 Desvenlafaxine Succinate 55 EDSS 55 EQUETRO 55 macular thickness 55 Abnormal Involuntary Movement 55 ascending dose 55 hemodynamic variables 55 mRCC 55 Glycemic Control 55 RESIST studies 55 follicular lymphomas 55 secondary endpoint 55 atazanavir ritonavir 55 hematologic toxicity 55 serum bilirubin 55 6MWT 55 lumen diameter 55 Golimumab 55 elevated LDH 55 IMPACT DCM 55 lactate dehydrogenase 55 pulmonary exacerbations 55 neurocognitive function 55 serum ALT 55 ALSFRS R 55 Key secondary endpoints 55 insulin detemir 55 Gastrointestinal Stromal Tumors 55 Pred Forte 55 undetectable viral 55 C telopeptide 55 Lesion 55 leukocyte count 55 SIMPADICO 55 Insulin Therapy 55 GOUT 55 Echocardiographic 55 viral kinetics 55 PREZISTA ritonavir 55 serum thyroglobulin 55 uM 55 nonfatal MI 55 dyspareunia 55 histologic 55 thrombocytopenic 55 % CI #.#-#.# [003] 55 histological subtype 55 ≥ 55 urinary calcium 55 semiquantitative 55 Stage IIB 55 interferon beta therapy 55 serum HCV RNA 55 alemtuzumab treated 55 Randomized Evaluation 55 standard chemotherapy regimen 55 IFN alfa 55 nonmetastatic prostate cancer 55 hyperalgesia 55 aminotransferase levels 55 adenoma recurrence 55 atherogenic dyslipidemia 55 Adenomas 55 subtrochanteric 55 WOMAC TM 55 CHAMPION PCI 55 TRAIL R1 55 ANOVA 55 mg Lucentis 55 Sentinel Lymph Node Biopsy 55 genotypic resistance 55 Zometa hazard 55 Geriatric Depression 55 reactogenicity 55 ULORIC 55 receiving ISENTRESS 55 PEGylated anti 55 annualized relapse 55 ELISPOT 55 HI titers 55 T2 lesion volume 55 APTIVUS R 55 repigmentation 55 Coronary Artery Calcium 55 serum leptin 55 rFSH 55 Neuropsychiatric Inventory NPI 55 plasma cortisol 55 paricalcitol 55 Visual acuity 55 undergone radical prostatectomy 55 episodic migraine 55 Hemoglobin A1c 55 #Gy 55 Mammographic 55 Peg IFN 55 baseline HbA1c 55 crossclamp 55 antithymocyte globulin 55 advanced adenomas 55 Nonspecific 55 Durezol 55 insulin glulisine 55 coronary calcification 55 sham injections 55 carotid IMT 55 bleeding pallor 55 fluorodeoxyglucose positron emission tomography 55 autoantibody positive 55 p = #.# [003] 55 chlorambucil 55 nasopharyngitis headache 55 endometrial thickness 55 intraabdominal 55 Nephrol Dial Transplant 55 severe periodontitis 55 Mg Usa 55 plus MTX 55 glycosylated hemoglobin 55 perioperatively 55 bladder carcinoma 55 Is Well Tolerated 55 Stroke Scale 55 urothelial 55 Teriflunomide 55 pretreatment serum 55 rimonabant #mg/day 55 tipranavir ritonavir 55 squamous histology 55 methylmalonic acid 55 Arch Intern Med 55 mg administered orally 55 Symptom Severity 55 log# copies mL 55 ARCALYST ® 55 Relapsed Refractory 55 moderate hepatic impairment 55 plasma renin activity 55 mcg dose 55 serum homocysteine 55 Intravenous immunoglobulin 55 severe neutropenia 55 ibandronate 55 Tasigna prolongs 55 induced sputum 55 RoACTEMRA 55 dose cytarabine 55 DEXA scan 55 #mg doses [002] 55 treatment naive genotype 55 triiodothyronine 55 rilonacept 55 transaminase 55 posttransplant 55 mcg linaclotide 55 imatinib therapy 55 extracranial 55 ER CHOP 55 intravenous tPA 55 REVIVE Diabetes 55 prospective observational cohort 55 Functional Capacity 55 #mg dose [002] 55 nicardipine 55 Bosutinib 55 Physical Component 55 invasive carcinomas 55 mg kg hr 55 generalized edema 55 pulmonary arterial 55 adefovir treated 55 URTI 55 placebo fluoxetine 55 autonomic dysfunction 55 -#.# mg dL [002] 55 weekly subcutaneous injections 55 FOLFOX4 55 normothermic 55 myocardial necrosis